Relative quantity of inflammatory genes from SDD patients pre and post treatment with Placebo (P) or Mesalazine (M) (Median [inter-quartile range])
| Median (IQR) | P group | p Value | M group | p Value | ||
| Genes | Pre | Post | Pre | Post | ||
| NOD2 | 0.8938 (0.76–1.57) | 1.021 (0.60–1.55) | 0.6632 | 1.359 (0.79–1.96) | 0.5925 (0.40–0.94) | 0.0002 |
| PAR2 | 1.841 (1.40–2.34) | 1.571 (1.20–2.08) | 0.4080 | 1.944 (1.49–3.37) | 1.056 (0.77–1.25) | 0.0007 |
| TNFα | 0.6611 (0.47–1.05) | 0.6341 (0.34–1.15) | 0.2977 | 0.9170 (0.61–1.40) | 0.4435 (0.36–0.69) | 0.0034 |
| IL1B | 0.7416 (0.47–1.40) | 1.092 (0.37–1.49) | 0.2575 | 0.9633 (0.37–1.96) | 0.6220 (0.37–1.01) | 0.0024 |
| TLR4 | 1.377 (0.94–2.49) | 1.465 (1.05–1.94) | 0.3604 | 1.537 (1.01–1.96) | 0.8932 (0.70–1.52) | 0.0479 |
| TLR9 | 0.4506 (0.34–0.73) | 0.5264 (0.30–0.68) | 0.4488 | 0.7991 (0.39–1.17) | 0.4976 (0.32–0.64) | 0.0215 |
| MYD88 | 1.765 (1.51–2.66) | 1.678 (1.22–2.44) | 0.6013 | 1.780 (1.15–2.99) | 1.134 (0.90–1.76) | 0.0105 |